ProCE Banner Activity

Pharmacologic Options for Bipolar Depression

Clinical Thought

Although a majority of symptomatic time in bipolar disorder I and II is spent in a depressive state, most medication approvals focus on manic or mixed symptoms. In this clinical commentary, Austin Campbell, PharmD, BCCP, provides valuable insight into the treatment armamentarium for depressive symptoms in bipolar disorder so that healthcare professionals are armed with information to choose the best option for their patients.

Released: November 30, 2022

Expiration: November 29, 2023

Share

Faculty

Austin Campbell

Austin Campbell, PharmD, BCCP

Clinical Associate Professor
UMKC School of Pharmacy at MU
Adjunct Assistant Professor
University of Missouri School of Medicine
Columbia, Missouri

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

Intra Cellular Therapies

Faculty Disclosure

Primary Author

Austin Campbell, PharmD, BCCP

Clinical Associate Professor
UMKC School of Pharmacy at MU
Adjunct Assistant Professor
University of Missouri School of Medicine
Columbia, Missouri

Austin Campbell, PharmD, BCCP: consultant/advisor/speaker: Intra-Cellular, Sunovion.